- Ainos ( NASDAQ: AIMD ) filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation Veldona to treat mild symptoms related to COVID-19.
- Earlier in August, the company said that it had started a phase 2 trial of Veldona in patients with mild COVID-19 in Taiwan, following results from preclinical studies.
- "Our Company is investigating whether impaired type I IFN could be related to persistent high blood viral loads and inflammatory responses in COVID-19 cases," said Chairman President and CEO Chun-Hsien Tsai.
- AIMD +5.28% to $2.59 premarket Aug. 24
For further details see:
Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19